Prospective study on the [ 18 F]FDOPA PET/CT role in the management of medullary thyroid cancer patients with high residual calcitonin level after surgery.

Eur J Nucl Med Mol ImagingJun 24, 2026 (epub)
Clinical ResearchEndocrinologyOncology (Medical)

Marie Terroir, Amelie Lusque, Elif Hindié et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter prospective study evaluated the role of [18F]FDOPA PET/CT in managing medullary thyroid cancer (MTC) patients with high residual calcitonin levels post-surgery. Among 24 patients, [18F]FDOPA detected 1.5 times more metastatic lymph nodes compared to conventional imaging, leading to a change in management for 58.3% of patients.

Key findings

  • [18F]FDOPA detected 1.5 times more metastatic lymph nodes compared to conventional imaging.
  • The discordance rate between [18F]FDOPA and conventional imaging was 46.4%.
  • Management changes occurred in 58.3% of patients based on [18F]FDOPA results.
  • The discordance rate for [18F]FDOPA reading was 20.8%.

Why it matters

The findings suggest that [18F]FDOPA PET/CT can significantly enhance the detection of metastatic lymph nodes in MTC patients, potentially leading to more informed management decisions. This could improve patient outcomes by ensuring appropriate treatment strategies.

Source

PubMed · PMID 42337037

Published in Eur J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.